Skyrizi Growth Slows Slightly, Testing AbbVie's Post-Humira Narrative

Earnings
โดย Yahoo Finance·Read original
Summary · why it matters

AbbVie's immunology drug Skyrizi posted 29.2% year-over-year revenue growth in the latest quarter, a slight deceleration from 31.9% operational growth in the prior quarter. Skyrizi generated $4.5 billion of AbbVie's $15 billion in total net revenues, and its growth rate is more than double the company's overall sales growth of 12.4%. The drug is the primary engine of AbbVie's post-Humira era, and any sustained slowdown could pressure the stock's valuation, which currently prices in continued high growth. Skeptics have pointed to intensifying competition in immunology, and this deceleration may be seen as an early sign of competitor friction. The next Skyrizi growth figure will be closely watched to determine whether this quarter marks a one-time blip or the start of a slower growth trajectory.

Impact on stocks 5

Biotech & Genomic Medicine▼ · 5 stocks
AbbVie Inc
ABBV
▼ NegativeDemandrelevance

Skyrizi growth decelerated to 29.2% from 31.9%, signaling potential demand slowdown for AbbVie's key drug.

Bristol-Myers Squibb Company
BMY
± MixedCompetitionrelevance

Article mentions intensifying competition in immunology, which could affect Bristol-Myers Squibb, but no specific impact on its drugs.

Johnson & Johnson
JNJ
± MixedCompetitionrelevance

Article mentions intensifying competition in immunology, which could affect Johnson & Johnson, but no specific impact on its drugs.

Merck & Company Inc
MRK
± MixedCompetitionrelevance

Article mentions intensifying competition in immunology, which could affect Merck, but no specific impact on its drugs.

Pfizer Inc
PFE
± MixedCompetitionrelevance

Article mentions intensifying competition in immunology, which could affect Pfizer, but no specific impact on its drugs.

© 2026 MarketDXNews